Conditions: Metastatic Renal Cell Carcinoma
Keywords: Metastatic Renal Cell Carcinoma Second Line Everolimus RAD001
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 134
Healthy volunteers: no

Brief summary:
This study will evaluate everolimus as second-line therapy in patients with metastatic renal cell carcinoma. Each patient will be enrolled and stratified in one of three cohorts based upon their first-line therapy: 1) prior cytokines, 2) prior sunitinib, or 3) prior anti-VEGF therapy other than sunitinib.

Detailed description:

Arms:
arm 1: Participants, received RAD001 10 mg orally once daily.

Interventions: intervention 1: RAD001
Intervention descriptions: intervention 1: Study drug was supplied as 5 mg tablets in blister packs.

Protocol document: